Intrexon | XON - Current Liabilities


Intrexon reported $23.02M in Current Liabilities for its fiscal quarter ending in June of 2024.





Current Liabilities Change Date
Agenus USD 249.24M 74.25M Mar/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
Amgen USD 24.96B 534M Mar/2026
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Intrexon USD 23.02M 38K Jun/2024
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
MannKind USD 134.56M 36.47M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Thermo Fisher Scientific USD 14.62B 568M Mar/2026
Veracyte USD 56.11M 3.82M Mar/2026
Xencor USD 73.46M 22.45M Mar/2026